ALDH1A1 and lung carcinoma: In conclusion, we show for the first time the benefit of using dual inhibitors of ALDH1 and ALDH3 as redox-disrupting agents in lung carcinomas and provide preclinical support for their use as monotherapies or in combination with other ROS-targeting drugs in NSCLCs, including chemoresistant tumors.